Tokenization Could Save Australian Economy $16.7 Billion Annually, Aussie Central Bank Reports – Featured Bitcoin News

Project Acacia Findings The Reserve Bank of Australia has officially moved past the “trial phase” of digital finance, signaling a major shift toward the real-world implementation of tokenized assets and wholesale digital currencies. In a key speech delivered March 25, RBA Assistant Governor Brad Jones made it clear: The question is no longer if Australia…

Read More

Bryan Johnson: Psychedelics may revolutionize anti-aging, psilocybin enhances neuroplasticity for mental health, and the default mode network’s role in cognitive rejuvenation

Key Takeaways Psychedelics are being explored as potential rejuvenation protocols for anti-aging. Research on psilocybin indicates it may have significant longevity benefits. Psilocybin affects the brain by dampening the default mode network, impacting self and ego perception. As people age, their experience of reality narrows due to the stiffening of their default mode network. Psilocybin…

Read More

Bitwise says Circle stock selloff is overdone, eyes $75B valuation by 2030

Bitwise CIO Matt Hougan says Circle’s 22% post-CLARITY Act selloff is “excessive,” arguing USDC’s payments moat and a $1.9t stablecoin market by 2030 justify a $75b valuation target. Summary Bitwise CIO Matt Hougan called Circle’s post-regulatory selloff “excessive,” projecting the stablecoin issuer could be worth $75 billion by 2030. Hougan cited Citigroup’s revised forecast that…

Read More

Metanova Labs: Bittensor revolutionizes drug discovery with decentralized virtual screening, combinatorial reactions expand possibilities to 65 billion, and dual incentives drive innovation

Key takeaways Bittensor is a decentralized network that uses crypto incentives to reward contributions to AI models and compute. The network can support a variety of applications, including drug discovery and renting compute resources. Subnets in Bittensor involve three main actors: subnet owners/operators, miners, and validators. The drug discovery process is currently costly and time-consuming,…

Read More